- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- January 2018
- 618 Pages
Global
From €21139EUR$22,000USD£18,146GBP
- Report
- May 2021
- 120 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- February 2021
- 120 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- August 2022
United States
From €1864EUR$1,940USD£1,600GBP
- Report
- August 2022
Global
From €1047EUR$1,090USD£899GBP
- Report
- February 2021
Global
From €2844EUR$2,960USD£2,442GBP
- Report
- July 2021
- 52 Pages
Global
From €3358EUR$3,495USD£2,883GBP
- Report
- October 2022
- 60 Pages
Global
From €3358EUR$3,495USD£2,883GBP
- Report
- June 2018
- 49 Pages
Global
From €3358EUR$3,495USD£2,883GBP
- Drug Pipelines
- September 2020
- 103 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- April 2023
- 196 Pages
China
From €3843EUR$4,000USD£3,299GBP
- Report
- April 2023
- 63 Pages
China
From €1730EUR$1,800USD£1,485GBP
- Report
- July 2023
- 90 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- August 2023
- 90 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- June 2022
- 74 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- May 2022
- 44 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- April 2023
- 81 Pages
China
From €1730EUR$1,800USD£1,485GBP
- Report
- October 2022
- 290 Pages
Global
From €5506EUR$5,730USD£4,726GBP
- Report
- November 2021
- 220 Pages
Global
From €5926EUR$6,168USD£5,088GBP
The Hepatitis Drug market is a subset of the Infectious Diseases Drugs market, which includes treatments for a variety of illnesses caused by microorganisms. Hepatitis drugs are used to treat viral infections of the liver, including hepatitis A, B, and C. These drugs can be used to reduce symptoms, prevent further damage to the liver, and even cure the infection. Common treatments include antiviral medications, interferon, and direct-acting antivirals.
The Hepatitis Drug market is highly competitive, with many companies offering treatments for different types of hepatitis. Some of the major players in the market include AbbVie, Gilead Sciences, Merck, Bristol-Myers Squibb, and Novartis. Other companies such as Cipla, Mylan, and Teva Pharmaceuticals also offer treatments for hepatitis. Show Less Read more